Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 17 new employees on July 16, 2021. A total of 45,200 stock options and 20,235 RSUs were issued, with stock options priced at $64.33 per share, equal to the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year, and the remaining 75% vesting monthly. The RSUs also have a four-year vesting schedule. This grant complies with Nasdaq Listing Rule 5635(c)(4).
- Inducement stock options and RSUs granted to 17 new employees signify recruitment growth.
- Stock options priced at $64.33 align with market conditions on the grant date.
- No significant economic or financial impact on current shareholders.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 16, 2021, the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 45,200 shares of its common stock and 20,235 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of July 16, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it’s done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005012/en/
FAQ
What is the significance of the inducement stock options granted by Arena Pharmaceuticals on July 16, 2021?
How many employees received stock options from Arena Pharmaceuticals?
What was the exercise price for the stock options granted by Arena Pharmaceuticals?
What is the vesting schedule for the RSUs granted by Arena Pharmaceuticals?